Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free CNTX Stock Alerts

Context Therapeutics (CNTX) Financials

Context Therapeutics logo
$0.60 -0.01 (-2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$0.61 +0.01 (+1.50%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Context Therapeutics

Annual Income Statements for Context Therapeutics

This table shows Context Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 6.64 -10 -15 -24 -27 -36
Consolidated Net Income / (Loss)		 6.64 -10 -15 -24 -27 -36
Net Income / (Loss) Continuing Operations		 6.64 -10 -15 -24 -27 -36
Total Pre-Tax Income 		6.64 -11 -15 -24 -27 -36
Total Operating Income		 -2.57 -11 -15 -25 -30 -40
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.57 11 15 25 30 40
Selling, General & Admin Expense		 0.93 3.63 7.79 7.29 7.22 7.85
Research & Development Expense		 1.64 6.89 7.59 18 23 32
Total Other Income / (Expense), net		 9.22 -0.05 0.55 1.11 3.20 3.58
Interest & Investment Income		 - - - 1.16 3.20 3.38
Other Income / (Expense), net		 9.88 0.01 -0.00 -0.06 -0.00 0.20
Basic Earnings per Share		 $3.07 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Weighted Average Basic Shares Outstanding		 348.37K 2.83M 15.97M 15.97M 58.42M 95.19M
Diluted Earnings per Share		 ($3.96) ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Weighted Average Diluted Shares Outstanding		 2.05M 2.83M 15.97M 15.97M 58.42M 95.19M
Weighted Average Basic & Diluted Shares Outstanding		 - 15.97M 15.97M 15.97M 89.70M 91.88M

Quarterly Income Statements for Context Therapeutics

This table shows Context Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Consolidated Net Income / (Loss)		 -5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Net Income / (Loss) Continuing Operations		 -5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Total Pre-Tax Income 		-5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Total Operating Income		 -6.18 -6.93 -3.82 -3.09 -19 -4.31 -5.53 -9.76 -11 -14 -9.34
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.18 6.93 3.82 3.09 19 4.31 5.53 9.76 11 14 9.34
Selling, General & Admin Expense		 1.70 1.63 1.85 1.70 1.88 1.79 2.07 1.93 1.89 1.96 2.33
Research & Development Expense		 4.49 5.30 1.97 1.38 17 2.52 3.46 7.83 8.72 12 7.02
Total Other Income / (Expense), net		 0.31 0.16 0.16 0.83 1.24 0.97 0.95 0.93 0.92 0.78 0.66
Interest & Investment Income		 - - 0.15 0.84 1.24 0.96 0.96 0.90 0.83 0.68 0.52
Other Income / (Expense), net		 0.02 -0.06 0.00 -0.01 -0.00 0.00 -0.01 0.03 0.08 0.10 0.14
Basic Earnings per Share		 ($0.37) ($0.42) ($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09)
Weighted Average Basic Shares Outstanding		 15.97M 15.97M 15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M
Diluted Earnings per Share		 ($0.37) ($0.42) ($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09)
Weighted Average Diluted Shares Outstanding		 15.97M 15.97M 15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M
Weighted Average Basic & Diluted Shares Outstanding		 15.97M 15.97M 75.00M 75.00M 75.00M 89.70M 89.70M 89.70M 91.88M 91.88M 91.88M

Annual Cash Flow Statements for Context Therapeutics

This table details how cash moves in and out of Context Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.11 49 -14 -21 80 -28
Net Cash From Operating Activities		 -1.03 -8.80 -14 -21 -15 -26
Net Cash From Continuing Operating Activities		 -1.03 -8.80 -14 -21 -15 -26
Net Income / (Loss) Continuing Operations		 6.64 -10 -15 -24 -27 -36
Consolidated Net Income / (Loss)		 6.64 -10 -15 -24 -27 -36
Depreciation Expense		 - 0.00 0.01 0.01 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income		 -9.00 3.88 1.38 1.08 16 3.44
Changes in Operating Assets and Liabilities, net		 1.32 -2.22 -0.20 1.78 -3.43 6.28
Net Cash From Investing Activities		 0.00 -0.25 -0.54 0.00 -15 -2.03
Net Cash From Continuing Investing Activities		 0.00 -0.25 -0.54 0.00 -15 -2.03
Purchase of Property, Plant & Equipment		 - 0.00 -0.04 0.00 -0.01 -0.03
Acquisitions		 0.00 -0.25 -0.50 0.00 -15 -2.00
Net Cash From Financing Activities		 1.15 58 -0.10 0.00 109 -0.02
Net Cash From Continuing Financing Activities		 1.15 58 -0.10 0.00 109 -0.02
Repurchase of Common Equity		 - 0.00 -0.10 - 0.00 -0.02
Issuance of Common Equity		 0.00 53 - 0.00 109 0.00

Quarterly Cash Flow Statements for Context Therapeutics

This table details how cash moves in and out of Context Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.46 -7.23 -4.36 91 -17 9.63 -5.08 -5.84 -6.58 -11 -11
Net Cash From Operating Activities		 -3.46 -7.23 -4.36 -3.36 -1.93 -4.91 -5.03 -5.84 -6.58 -8.94 -11
Net Cash From Continuing Operating Activities		 -3.46 -7.28 -4.36 -3.36 -1.93 -4.91 -5.03 -5.84 -6.58 -8.94 -11
Net Income / (Loss) Continuing Operations		 -5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Consolidated Net Income / (Loss)		 -5.87 -6.77 -3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68
Depreciation Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense		 0.01 - 0.00 - 15 - 0.03 0.03 0.03 - 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.25 0.26 0.24 0.16 0.21 15 0.29 0.39 0.32 2.43 0.41
Changes in Operating Assets and Liabilities, net		 2.15 -0.72 -0.94 -1.26 0.54 -1.78 -0.77 2.57 2.76 1.73 -3.19
Net Cash From Investing Activities		 - - 0.00 - -15 - -0.03 - - -2.00 -0.04
Net Cash From Continuing Investing Activities		 - - 0.00 - -15 - -0.03 - - -2.00 -0.04
Purchase of Property, Plant & Equipment		 - - 0.00 - -0.01 - -0.03 - - - -0.04
Net Cash From Financing Activities		 - - 0.00 95 -0.04 15 -0.02 - - - 0.00
Net Cash From Continuing Financing Activities		 - - 0.00 95 -0.04 15 -0.02 - - - 0.00
Issuance of Common Equity		 - - - - -0.04 15 -0.02 - - - 0.00

Annual Balance Sheets for Context Therapeutics

This table presents Context Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.47 51 38 16 98 68
Total Current Assets		 0.30 51 38 16 98 68
Cash & Equivalents		 0.29 50 35 14 94 66
Prepaid Expenses		 0.01 1.62 2.36 1.60 3.47 2.36
Plant, Property, & Equipment, net		 0.00 0.00 0.03 0.02 0.01 0.03
Total Noncurrent Assets		 0.17 0.05 0.08 0.00 0.22 0.11
Other Noncurrent Operating Assets		 0.17 0.05 0.08 0.00 0.22 0.11
Total Liabilities & Shareholders' Equity		 0.47 51 38 16 98 68
Total Liabilities		 9.62 3.03 3.21 4.19 2.86 8.02
Total Current Liabilities		 9.55 3.03 3.21 4.19 2.75 8.02
Accounts Payable		 2.71 1.83 0.94 2.38 1.45 2.53
Accrued Expenses		 0.96 1.21 2.22 1.81 1.19 5.38
Other Current Liabilities		 - 0.00 0.06 0.00 0.11 0.11
Total Noncurrent Liabilities		 0.07 0.00 0.00 0.00 0.11 0.00
Other Noncurrent Operating Liabilities		 - - - 0.00 0.11 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -17 48 35 12 95 60
Total Preferred & Common Equity		 -17 48 35 12 95 60
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -17 48 35 12 95 60
Common Stock		 1.88 78 79 80 190 191
Retained Earnings		 -19 -29 -44 -68 -95 -131

Quarterly Balance Sheets for Context Therapeutics

This table presents Context Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 23 11 103 86 93 87 79 59
Total Current Assets		 23 11 103 86 93 87 79 59
Cash & Equivalents		 22 10 102 85 89 84 77 55
Prepaid Expenses		 1.29 0.95 1.16 1.27 3.38 3.43 2.12 3.99
Plant, Property, & Equipment, net		 0.02 0.01 0.01 0.01 0.04 0.04 0.03 0.06
Total Noncurrent Assets		 0.00 0.00 0.00 0.24 0.19 0.17 0.14 0.28
Noncurrent Note & Lease Receivables		 - - - 0.24 0.19 0.17 0.14 0.28
Total Liabilities & Shareholders' Equity		 23 11 103 86 93 87 79 59
Total Liabilities		 4.60 2.61 1.60 2.47 1.98 4.61 6.06 6.66
Total Current Liabilities		 4.60 2.61 1.60 2.33 1.90 4.56 6.04 6.53
Accounts Payable		 1.83 2.05 0.61 1.03 1.00 2.40 2.72 2.47
Accrued Expenses		 2.78 0.56 0.99 1.20 0.79 2.04 3.20 3.91
Other Current Liabilities		 0.00 - - 0.10 0.11 0.11 0.12 0.16
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.14 0.08 0.05 0.02 0.12
Other Noncurrent Operating Liabilities		 - - - 0.14 0.08 0.05 0.02 0.12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 18 8.44 101 84 91 83 73 52
Total Preferred & Common Equity		 18 8.44 101 84 91 83 73 52
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 18 8.44 101 84 91 83 73 52
Common Stock		 80 80 175 175 190 191 191 192
Retained Earnings		 -61 -72 -74 -91 -99 -108 -118 -140

Annual Metrics And Ratios for Context Therapeutics

This table displays calculated financial ratios and metrics derived from Context Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 10,963,966.00 15,966,053.00 15,966,053.00 74,998,312.00 91,879,177.00
DEI Adjusted Shares Outstanding		 0.00 10,963,966.00 15,966,053.00 15,966,053.00 74,998,312.00 91,879,177.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.95 -0.93 -1.50 -0.36 -0.39
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -243.95% -46.19% -63.37% -19.10% -32.00%
EBIT Growth		 0.00% -243.95% -46.28% -63.35% -19.09% -32.00%
NOPAT Growth		 0.00% -186.45% -46.13% -63.01% -19.35% -32.68%
Net Income Growth		 0.00% -257.38% -41.88% -61.53% -11.52% -35.17%
EPS Growth		 0.00% 6.82% 74.80% -61.29% 69.33% 17.39%
Operating Cash Flow Growth		 0.00% -750.50% -53.98% -55.34% 30.84% -81.26%
Free Cash Flow Firm Growth		 0.00% 0.00% -20.00% -37.93% -55.06% 12.02%
Invested Capital Growth		 0.00% 60.92% 45.77% -248.92% 132.44% -760.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -5.41% -14.12% 8.24% -31.24%
EBIT Q/Q Growth		 0.00% 0.00% -5.43% -14.11% 8.24% -31.23%
NOPAT Q/Q Growth		 0.00% 0.00% -5.42% -13.85% 8.06% -31.43%
Net Income Q/Q Growth		 0.00% 0.00% -3.24% -15.48% 11.37% -36.62%
EPS Q/Q Growth		 0.00% 0.00% -105.70% -15.38% 49.45% -80.95%
Operating Cash Flow Q/Q Growth		 0.00% -119.23% 7.08% -18.58% 13.75% -18.06%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -16.56% 3.06% -16.96%
Invested Capital Q/Q Growth		 0.00% 0.00% 45.48% 21.67% 188.61% -46.69%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 98.83% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.95% 100.61% 96.44% 95.37% 89.31% 91.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -72.62% -53.46% -35.74% -102.79% -49.89% -46.39%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -2,912.59% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -134.29% -42.84% -35.74% -102.79% -49.89% -46.39%
Return on Equity Simple (ROE_SIMPLE)		 -39.27% -21.66% -42.68% -201.87% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.57 -7.37 -11 -18 -21 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -162.76% -14.05% -9.56% -25.68% -10.61% -10.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -147.85% -21.99% -45.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 7.31 -11 -15 -25 -30 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 7.31 -11 -15 -25 -30 -39
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.60 0.30 1.52 0.83 2.23
Price to Tangible Book Value (P/TBV)		 0.00 0.60 0.30 1.52 0.83 2.23
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 3.76 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 26.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 5.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 5.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.65 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.62 -1.12 -1.03 -1.07 -1.02 -1.03
Leverage Ratio		 -0.05 1.32 1.08 1.16 1.07 1.07
Compound Leverage Factor		 -0.05 1.33 1.04 1.11 0.95 0.98
Debt to Total Capital		 -186.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -184.09% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -2.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -243.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 529.36% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.81 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.78 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.31 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -2.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.03 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -26.91 5.42 0.08 -7.63 15.32 6.58
Noncontrolling Interest Sharing Ratio		 -84.93% 19.86% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.03 16.90 11.80 3.83 35.62 8.52
Quick Ratio		 0.03 16.36 11.07 3.45 34.36 8.23
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.49 -11 -16 -24 -21
Operating Cash Flow to CapEx		 0.00% 0.00% -36,782.59% 0.00% -198,967.11% -77,722.93%
Free Cash Flow to Firm to Interest Expense		 0.00 -147.76 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -1.56 -136.98 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1.56 -136.98 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.49 -1.36 -0.74 -2.58 0.84 -5.52
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 2.12 0.62 -1.84 3.42 -6.36
Enterprise Value (EV)		 38 -20 -25 3.59 -16 69
Market Capitalization		 25 29 10 18 79 135
Book Value per Share		 ($48.57) $4.40 $2.18 $0.74 $1.27 $0.66
Tangible Book Value per Share		 ($48.57) $4.40 $2.18 $0.74 $1.27 $0.66
Total Capital		 -3.20 48 35 12 95 60
Total Debt		 5.95 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.07 0.00 0.00 0.00 0.00 0.00
Net Debt		 5.66 -50 -35 -14 -94 -66
Capital Expenditures (CapEx)		 0.00 0.00 0.04 0.00 0.01 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.66 -1.41 -0.85 -2.59 0.72 -5.66
Debt-free Net Working Capital (DFNWC)		 -3.36 48 35 12 95 60
Net Working Capital (NWC)		 -9.25 48 35 12 95 60
Net Nonoperating Expense (NNE)		 -9.22 3.09 4.07 6.41 5.78 8.33
Net Nonoperating Obligations (NNO)		 5.66 -50 -35 -14 -94 -66
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.01 0.01 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.83M 15.97M 15.97M 58.42M 95.19M
Adjusted Diluted Earnings per Share		 $0.00 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.83M 15.97M 15.97M 58.42M 95.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 15.97M 15.97M 15.97M 89.70M 91.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.80 -7.37 -11 -18 -21 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 11.05 -163.71 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -3.89 -114.70 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 11.05 -163.71 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.89 -114.70 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.69% 0.00% 0.00% -0.04%

Quarterly Metrics And Ratios for Context Therapeutics

This table displays calculated financial ratios and metrics derived from Context Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 15,966,053.00 15,966,053.00 15,966,053.00 74,998,312.00 74,998,312.00 74,998,312.00 89,704,194.00 89,704,194.00 89,704,194.00 91,879,177.00 91,879,177.00
DEI Adjusted Shares Outstanding		 15,966,053.00 15,966,053.00 15,966,053.00 74,998,312.00 74,998,312.00 74,998,312.00 89,704,194.00 89,704,194.00 89,704,194.00 91,879,177.00 91,879,177.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.37 -0.42 -0.23 -0.03 -0.23 -0.04 -0.05 -0.10 -0.11 -0.14 -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -52.21% -80.25% 42.49% 41.43% 36.08% 38.44% -44.22% -213.72% -166.77% -218.40% -66.46%
EBIT Growth		 -52.35% -80.16% 42.67% 41.66% -203.38% 38.42% -44.91% -214.45% 43.72% -218.28% -66.20%
NOPAT Growth		 -52.68% -78.58% 42.65% 41.64% -202.59% 37.83% -44.61% -215.95% 43.26% -220.26% -68.99%
Net Income Growth		 -52.42% -90.34% 41.86% 55.01% -197.21% 50.62% -24.80% -291.55% 44.48% -289.65% -89.65%
EPS Growth		 -54.17% -90.91% 42.50% 87.10% 40.54% 107.14% 78.26% -125.00% 54.55% -566.67% -80.00%
Operating Cash Flow Growth		 -15.59% -83.91% 23.88% 27.54% 44.14% 32.11% -15.31% -73.89% -240.29% -82.26% -127.30%
Free Cash Flow Firm Growth		 40.94% 9.81% 47.45% 25.35% -546.04% -113.46% -245.82% -119.72% 70.16% 48.62% 63.85%
Invested Capital Growth		 -142.85% -248.92% -58.85% 61.85% 71.33% 132.44% 199.06% -125.00% -298.76% -760.12% -242.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -16.58% -13.61% 45.40% 19.00% -27.24% -9.40% -27.92% -76.19% -8.20% -30.57% 33.12%
EBIT Q/Q Growth		 -16.22% -13.45% 45.38% 18.99% -504.38% 76.97% -28.53% -75.79% -8.18% -30.22% 32.88%
NOPAT Q/Q Growth		 -16.78% -12.18% 44.85% 19.22% -505.51% 76.95% -28.27% -76.49% -8.73% -30.10% 32.31%
Net Income Q/Q Growth		 -17.23% -15.24% 45.82% 38.53% -674.44% 80.85% -36.92% -92.86% -9.81% -34.38% 33.36%
EPS Q/Q Growth		 -19.35% -13.51% 45.24% 82.61% -450.00% 113.64% -266.67% -80.00% -11.11% -40.00% 35.71%
Operating Cash Flow Q/Q Growth		 25.27% -108.82% 39.66% 23.04% 42.39% -153.80% -2.48% -16.04% -12.74% -35.93% -27.80%
Free Cash Flow Firm Q/Q Growth		 37.69% -26.10% 31.42% -38.53% -439.28% 58.34% -11.10% 11.98% 26.76% 28.26% 21.82%
Invested Capital Q/Q Growth		 -190.49% 21.67% 36.17% 73.73% -118.34% 188.61% 94.93% -159.66% -286.96% -46.69% 57.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.29% 96.79% 96.01% 72.85% 93.35% 77.62% 82.69% 90.71% 92.08% 95.02% 94.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.51% -102.79% -114.72% -29.68% -58.98% -49.89% -55.59% -37.25% -33.68% -46.39% -56.19%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -2,912.59% -1,558.86% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -73.51% -102.79% -114.72% -29.68% -58.98% -49.89% -55.59% -37.25% -33.68% -46.39% -56.19%
Return on Equity Simple (ROE_SIMPLE)		 -112.87% 0.00% -252.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.33 -4.85 -2.68 -2.16 -13 -3.02 -3.87 -6.83 -7.43 -9.66 -6.54
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.07% -7.67% -4.97% -0.15% -8.21% -0.60% -1.42% -2.16% -2.80% -4.19% -2.97%
Return On Investment Capital (ROIC_SIMPLE)		 - -40.88% -31.70% -2.14% -15.61% -3.17% -4.25% -8.28% -10.15% -15.98% -12.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.17 -6.99 -3.82 -3.09 -19 -4.31 -5.54 -9.73 -11 -14 -9.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.15 -6.99 -3.82 -3.09 -3.93 -4.30 -5.51 -9.70 -10 -14 -9.16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.31 1.52 2.61 1.49 1.75 0.83 0.60 0.71 1.19 2.23 4.61
Price to Tangible Book Value (P/TBV)		 1.31 1.52 2.61 1.49 1.75 0.83 0.60 0.71 1.19 2.23 4.61
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.07 -1.07 -1.01 -1.04 -1.02 -1.00 -1.01 -1.03 -1.03 -1.00
Leverage Ratio		 1.15 1.16 1.16 1.04 1.07 1.07 1.05 1.03 1.05 1.07 1.06
Compound Leverage Factor		 1.10 1.12 1.11 0.76 1.00 0.83 0.87 0.94 0.97 1.02 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.52 -3.90 -4.24 56.31 34.64 16.18 16.09 6.68 7.19 7.83 18.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.99 3.83 4.23 64.01 36.91 35.62 48.80 19.09 13.10 8.52 8.96
Quick Ratio		 4.71 3.45 3.87 63.29 36.36 34.36 47.02 18.33 12.75 8.23 8.34
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.39 -3.01 -2.07 -2.86 -15 -6.43 -7.15 -6.29 -4.61 -3.31 -2.58
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -26,426.03% 0.00% -14,812.01% 0.00% 0.00% 0.00% -30,676.30%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.29 -2.58 -1.65 -0.43 -0.94 0.84 1.63 -0.97 -3.76 -5.52 -2.33
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.94 -1.84 -0.61 0.70 2.35 3.42 3.28 -0.54 -2.82 -6.36 -3.96
Enterprise Value (EV)		 2.43 3.59 12 49 62 -16 -34 -25 9.97 69 186
Market Capitalization		 24 18 22 150 147 79 55 59 87 135 241
Book Value per Share		 $1.15 $0.74 $0.53 $1.35 $1.12 $1.27 $1.01 $0.92 $0.82 $0.66 $0.57
Tangible Book Value per Share		 $1.15 $0.74 $0.53 $1.35 $1.12 $1.27 $1.01 $0.92 $0.82 $0.66 $0.57
Total Capital		 18 12 8.44 101 84 95 91 83 73 60 52
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -22 -14 -10 -102 -85 -94 -89 -84 -77 -66 -55
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.01 0.00 0.03 0.00 0.00 0.00 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.31 -2.59 -1.66 -0.44 -1.06 0.72 1.48 -1.12 -3.92 -5.66 -2.55
Debt-free Net Working Capital (DFNWC)		 18 12 8.43 101 84 95 91 82 73 60 52
Net Working Capital (NWC)		 18 12 8.43 101 84 95 91 82 73 60 52
Net Nonoperating Expense (NNE)		 1.55 1.92 0.99 0.09 4.37 0.33 0.71 2.00 2.27 3.36 2.14
Net Nonoperating Obligations (NNO)		 -22 -14 -10 -102 -85 -94 -89 -84 -77 -66 -55
Total Depreciation and Amortization (D&A)		 0.01 0.00 0.00 0.00 15 0.00 0.03 0.03 0.03 0.00 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.42) ($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 15.97M 15.97M 15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.42) ($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 15.97M 15.97M 15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 15.97M 15.97M 75.00M 75.00M 75.00M 89.70M 89.70M 89.70M 91.88M 91.88M 91.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.33 -4.85 -2.68 -2.16 -13 -3.02 -3.87 -6.83 -7.43 -9.66 -6.54
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 0.00%

Financials Breakdown Chart

Key Financial Trends

Context Therapeutics (NASDAQ: CNTX) remains a pre-revenue biotech with no product sales yet, so the story is still centered on cash burn, runway, and how efficiently the company is funding research and development. The latest quarter shows a much larger balance sheet than in prior years, but operating losses remain substantial.

What stands out most: Context ended Q1 2026 with $54.5 million in cash and equivalents, down from $76.9 million at the end of Q3 2025 and $89.4 million at the end of Q1 2025. That decline reflects continued negative operating cash flow, which was -$11.4 million in Q1 2026.

  • Cash on hand remains solid at $54.5 million, which gives the company meaningful near-term operating flexibility.
  • Q1 2026 operating loss improved to -$9.3 million from -$13.8 million in Q4 2025 and -$10.6 million in Q3 2025.
  • R&D spending fell sharply to $7.0 million in Q1 2026 from $11.8 million in Q4 2025, suggesting tighter cost control.
  • Net loss narrowed to -$8.7 million, better than -$13.0 million in Q4 2025 and -$9.7 million in Q3 2025.
  • The company generated $663,227 in other income in Q1 2026, mostly from interest and investment income, helping offset operating losses.
  • The company is still pre-revenue, with $0 in revenue across all reported quarters, so results depend entirely on pipeline progress and capital management.
  • Total liabilities were modest at $6.7 million in Q1 2026 versus $52.2 million in equity, indicating a relatively clean balance sheet for now.
  • Share count has drifted higher over time, with weighted average basic shares at 95.2 million in Q1 2026 versus 15.0 million to 16.0 million in early 2024, reflecting substantial dilution over the longer period.
  • Operating cash flow is still deeply negative at -$11.4 million in Q1 2026, meaning the business is consuming cash each quarter.
  • Cash fell by $11.5 million in the latest quarter, and the multi-quarter trend shows a steady reduction from $89.4 million in Q1 2025 to $54.5 million in Q1 2026.
  • The company has a long history of losses, including quarterly net losses of -$45.8 million in Q1 2025 and -$17.5 million in Q3 2024, underscoring the volatility in reported results and the dependence on financing.

Bottom line: Context Therapeutics enters 2026 with a healthier cash balance than many early-stage biotech peers, and recent quarterly losses have improved versus late 2025. Still, with no revenue and ongoing negative operating cash flow, investors should continue to focus on burn rate, pipeline milestones, and whether the current cash balance is enough to fund development without additional dilution.

07/18/26 12:29 AM ETAI Generated. May Contain Errors.

Context Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Context Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Context Therapeutics' net income appears to be on an upward trend, with a most recent value of -$36.12 million in 2025, falling from $6.64 million in 2020. The previous period was -$26.73 million in 2024. Check out Context Therapeutics' forecast to explore projected trends and price targets.

Context Therapeutics' total operating income in 2025 was -$39.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $39.70 million

Over the last 5 years, Context Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Context Therapeutics' total liabilities were at $8.02 million at the end of 2025, a 180.4% increase from 2024, and a 16.6% decrease since 2020.

In the past 5 years, Context Therapeutics' cash and equivalents has ranged from $290.67 thousand in 2020 to $94.43 million in 2024, and is currently $66.00 million as of their latest financial filing in 2025.

Over the last 5 years, Context Therapeutics' book value per share changed from -48.57 in 2020 to 0.66 in 2025, a change of -101.4%.


Related Companies

Financial statements for NASDAQ:CNTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel